Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record.

Olanzapine Versus Divalproex Versus Placebo in the Treatment of Mild to Moderate Mania: A Randomized, 12-Week, Double-Blind Study

Abstract

OBJECTIVE: To evaluate the efficacy and safety of olanzapine, divalproex, and placebo in a randomized, double-blind trial in mild to moderate mania (DSM-IV-TR criteria). METHOD: The study was conducted from October 2004 to December 2006. A total of 521 patients from private practices, hospitals, and university clinics were randomly assigned to olanzapine (5-20 mg/day), divalproex (500-2500 mg/day), or placebo for 3 weeks; those completing continued with a 9-week double-blind extension. Efficacy (mean change in Young Mania Rating Scale [YMRS] total score was the primary outcome) and safety were assessed. RESULTS: After 3 weeks of treatment, olanzapine-treated (N = 215) and placebo-treated (N = 105) patients significantly differed in YMRS baseline-to-endpoint total score change (p = .034; least squares [LS] mean: -9.4 and -7.4, respectively). Such changes were not significantly different between olanzapine vs. divalproex (N = 201) or divalproex vs. placebo. After 12 weeks of treatment, olanzapine- and divalproex-treated patients significantly differed in YMRS baseline-to-endpoint changes (p = .004; LS mean: -13.3 and -10.7, respectively). Of observed cases, 35.4% (35/99; 3 weeks) to 57.1% (28/49; 12 weeks) had valproate plasma concentrations lower than the recommended valproate therapeutic range, but these patients' YMRS scores were lower than those of patients with valproate concentrations above/within range. Compared with divalproex, after 12 weeks, olanzapine-treated patients had significant increases in weight (p < .001) and in glucose (p < .001), triglyceride (p = .003), cholesterol (p = .024), uric acid (p = .027), and prolactin (p < .001) levels. Divalproex-treated patients had significant decreases in leukocytes (p = .044) and platelets (p < .001) compared with olanzapine after 12 weeks of treatment. The incidence of potentially clinically significant weight gain (>/= 7% from baseline) was higher with olanzapine than with divalproex (3-week: p = .064, 6.4% vs. 2.7%; 12-week: p = .002, 18.8% vs. 8.5%; respectively). CONCLUSION: Olanzapine was significantly more efficacious than placebo but not divalproex at 3 weeks and significantly more efficacious than divalproex at 12 weeks. Olanzapine-treated patients had significantly greater increases in weight and in glucose, cholesterol, triglyceride, uric acid, and prolactin levels than divalproex-treated patients. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00094549.

Overview

Integrity signals

Registry

Crossref · 10.4088/jcp.v69n1113

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Still being checked.

Cited by

See all 87

Metadata

Authors
Tohen, M., Vieta, E., Goodwin, G. M., Sun, B., Amsterdam, J. D., Banov, M., Shekhar, A., Aaronson, S. T., Bardenstein, L., Grecu-Gabos, I., Tochilov, V., Prelipceanu, D., Oliff, H. S., Kryzhanovskaya, L., & Bowden, C.
Affiliations
  • Harvard University (US)
  • University of Oxford (GB)
  • Eli Lilly (United States) (US)
  • University of Pennsylvania (US)
  • Northwest Behavioral Medicine (US)
  • Indiana University – Purdue University Indianapolis (US)
  • Sheppard Pratt Health System (US)
  • North-Western State Medical University named after I.I. Mechnikov (RU)
  • Scientific Consulting Group (US)
  • The University of Texas at San Antonio Health Science Center (US)
Venue
The Journal of Clinical Psychiatry
Published
2008-11-30
Volume
69
Issue
11
Pages
1776-1789
ISSN
0160-6689 (ISSN-L)
OpenAlex
W2059471127
Cited by
87
References
0
Citations by year
2026: 1 · 2025: 4 · 2024: 4 · 2022: 1 · 2021: 2 · 2020: 2 · 2019: 4 · 2018: 5 · 2017: 4 · 2016: 5 · 2015: 7 · 2014: 2 · 2013: 2 · 2012: 14
FWCI
7.02
Type
journal article
Language
en
Open access
closed
Locations
  • The Journal of Clinical Psychiatry (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
Keywords
olanzapine, divalproex, valproic acid, mania, bipolar disorder, antipsychotic drugs, Young Mania Rating Scale, drug safety, weight gain, prolactin, leukopenia, hypertriglyceridemia, treatment efficacy comparison, adverse effects, mood stabilizers
MeSH terms
Olanzapine, Adolescent, Adult, Aged, Benzodiazepines, Bipolar Disorder, Dose-Response Relationship, Drug, Double-Blind Method, Female, Humans, Male, Middle Aged, Prolactin, Antipsychotic Agents, Valproic Acid, Weight Gain, Least-Squares Analysis, Antimanic Agents

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Olanzapine Versus Divalproex Versus Placebo in the Treatment of Mild to Moderate Mania: A Randomized, 12-Week, Double-Blind Study. https://app.cochat.ai/papers/10.4088/jcp.v69n1113
The paper
Tohen, M., Vieta, E., Goodwin, G. M., Sun, B., Amsterdam, J. D., Banov, M., Shekhar, A., Aaronson, S. T., Bardenstein, L., Grecu-Gabos, I., Tochilov, V., Prelipceanu, D., Oliff, H. S., Kryzhanovskaya, L., & Bowden, C. (2008). Olanzapine Versus Divalproex Versus Placebo in the Treatment of Mild to Moderate Mania: A Randomized, 12-Week, Double-Blind Study. The Journal of Clinical Psychiatry. https://doi.org/10.4088/jcp.v69n1113

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.